Published in Clin Cases Miner Bone Metab on September 01, 2009
Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital. BMC Health Serv Res (2016) 0.75
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. Osteoporos Int (2016) 0.75
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (2003) 16.18
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int (2002) 9.29
Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol (2004) 6.59
Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med (2007) 4.23
Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res (2001) 3.50
Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int (2005) 3.22
High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant (2007) 2.91
The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int (2007) 2.40
A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int (2004) 2.29
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol Dial Transplant (2006) 2.20
Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant (2007) 2.18
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ (1995) 2.10
Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol (2004) 2.08
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis (2008) 2.02
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis (2006) 1.97
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int (2005) 1.96
Vitamin D, shedding light on the development of disease in peripheral arteries. Arterioscler Thromb Vasc Biol (2004) 1.84
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis (2005) 1.69
Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. J Bone Miner Res (2000) 1.66
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int (2005) 1.64
The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis (2005) 1.60
Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int (2006) 1.60
Low bone turnover in patients with renal failure. Kidney Int Suppl (1999) 1.52
Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol (2007) 1.42
Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial (2007) 1.42
Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int (2005) 1.38
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis (2004) 1.31
Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial (2007) 1.31
Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N Engl J Med (1982) 1.29
Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet (1978) 1.29
Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res (2004) 1.22
Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet (1976) 1.22
Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis (2001) 1.14
Normal plasma-1,25-(OH)2-vitamin-D concentrations in nutritional osteomalacia. Lancet (1979) 1.11
1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int (1989) 1.06
Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant (2002) 1.05
Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant (1996) 1.05
Progression of coronary artery calcification in predialysis patients. Am J Nephrol (2007) 1.04
Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol (2004) 1.02
1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med (1978) 1.02
Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology (Carlton) (2008) 1.02
Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab (1992) 1.01
A possible role for propranolol in the treatment of renal osteodystrophy. Lancet (1978) 1.01
Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients. J Ren Nutr (2006) 0.97
Phosphate binders and management of hyperphosphataemia in end-stage renal disease. Nephrol Dial Transplant (2006) 0.97
Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int (1990) 0.96
Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant (1995) 0.95
Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int (1994) 0.95
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr (2006) 0.94
Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract (2008) 0.93
The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol (2005) 0.92
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant (2004) 0.89
On the evolving nature of understanding dialysis-related disorders. Am J Kidney Dis (2003) 0.89
Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc (1983) 0.88
Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail (2008) 0.87
The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy. Am J Med (1978) 0.87
The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology (1993) 0.84
Novel dosage forms and regimens for sevelamer-based phosphate binders. J Ren Nutr (2006) 0.83
Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther (2005) 0.82
Effect of pharmacological suppression of secondary hyperparathyroidism on cardiovascular hemodynamics in predialysis CKD patients: A preliminary observation. Hemodial Int (2007) 0.82
Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int (1976) 0.82
Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. Drugs (2007) 0.82
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. Am J Nephrol (2006) 0.82
Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant (2004) 0.81
Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results. Miner Electrolyte Metab (1986) 0.81
Vascular calcification and uremia: what do we know? Am J Nephrol (2007) 0.81
Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients. Kidney Int (1999) 0.81
Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J (Clin Res Ed) (1981) 0.80
Aluminum intoxication. N Engl J Med (1984) 0.80
Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrinol Metab (1999) 0.80
Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant (2002) 0.80
Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation. Nephron (1998) 0.79
Safety and efficacy of calcium carbonate in children with chronic renal failure. Nephrol Dial Transplant (1989) 0.78
Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy. Kidney Int (1980) 0.78
Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease. Expert Opin Pharmacother (2006) 0.78
Calcimimetics in CKD-results from recent clinical studies. Pediatr Nephrol (2008) 0.78
Calcifediol in chronic renal insufficiency. Skeletal response. JAMA (1976) 0.78
Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Clin Nephrol (1998) 0.78
Acute effects of calcium carbonate and citrate on secondary hyperparathyroidism in chronic renal failure. Am J Nephrol (1991) 0.78
Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med (1980) 0.77
Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol (2007) 0.77
Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. Br Med J (Clin Res Ed) (1985) 0.77
Suppression of secondary hyperparathyroidism by propranolol in renal failure patients. Nephron (1981) 0.76
Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency. Int Urol Nephrol (1978) 0.76
[Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure]. Nefrologia (2004) 0.76
New therapies for uremic secondary hyperparathyroidism. J Ren Nutr (2006) 0.76
[Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate]. Nefrologia (2003) 0.76
The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant (1998) 0.76
Alphacalcidol oral pulses normalize uremic hyperparathyroidism prior to dialysis. Pediatr Nephrol (1995) 0.76
Long-term low-dose calcitriol treatment in predialysis chronic renal failure: can it prevent hyperparathyroid bone disease? Nephrol Dial Transplant (1995) 0.76
Longitudinal study of bone mass in end-stage renal disease patients: effects of parathyroidectomy for renal osteodystrophy. J Bone Miner Res (1993) 0.76
Treatment of uremic hyperphosphatemia--is there still a need for aluminum salts? Am J Nephrol (1988) 0.76
The beneficial effect of ketoacids on serum phosphate and parathyroid hormone in patients with chronic uremia. Clin Nephrol (1988) 0.76
Is PTH a risk factor for cardiovascular calcifications in haemodialysis? Nephrol Dial Transplant (2007) 0.76
Long-term effects of histamine H2-receptor antagonists on serum parathyroid hormone in chronic renal failure. Clin Endocrinol (Oxf) (1985) 0.76
Effects of 1 alpha-hydroxyvitamin D3 on various stages of predialysis renal bone disease. Bone Miner (1989) 0.75
Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. Am J Kidney Dis (1995) 0.75
The role of dietary phosphorus restriction in the conservative management of chronic renal disease. J Ren Nutr (2005) 0.75